We Offer Worldwide Shipping
Login Wishlist

Duloxetine hydrochloride

$64

  • Brand : BIOFRON

  • Catalogue Number : BN-O1196

  • Specification : 98%(HPLC)

  • CAS number : 136434-34-9

  • Formula : C18H20ClNOS

  • Molecular Weight : 333.88

  • PUBCHEM ID : 60834

  • Volume : 5mg

Available on backorder

Quantity
Checkout Bulk Order?

Catalogue Number

BN-O1196

Analysis Method

Specification

98%(HPLC)

Storage

-20℃

Molecular Weight

333.88

Appearance

Powder

Botanical Source

Structure Type

Category

SMILES

CNCCC(C1=CC=CS1)OC2=CC=CC3=CC=CC=C32.Cl

Synonyms

2-thiophenepropanamine, N-methyl-γ-(1-naphthalenyloxy)-, (γS)-, hydrochloride/(S)-(+)-N-Methyl-3-(1-naphthyloxy)-3-(2-thienyl)propylamine Hydrochloride/(+)-(S)-N-methyl-g-(1-naphthyloxy)-2-thiophenepropylamine Hydrochloride/(3S)-N-methyl-3-(naphtalen-1-yloxy)-3-thiophen-2-ylpropan-1-amine chlorhydrate/(S)-Duloxetine hydrochloride/(3S)-N-Methyl-3-(1-naphthyloxy)-3-(2-thienyl)propan-1-amine hydrochloride (1:1)/(S)-N-Methyl-g-(1-naphthalenyloxy)-2-thiophenepropanamine Hydrochloride/duloxetine hcl/2-Thiophenepropanamine, N-methyl-γ-(1-naphthalenyloxy)-, (γS)-, hydrochloride (1:1)/(S)-N-Methyl-3-(naphthalen-1-yloxy)-3-(thiophen-2-yl)propan-1-amine hydrochloride/(3S)-N-methyl-3-naphthalen-1-yloxy-3-thiophen-2-ylpropan-1-amine,hydrochloride/(3S)-N-Methyl-3-(1-naphthyloxy)-3-(2-thienyl)-1-propanamine hydrochloride (1:1)/(3S)-N-methyl-3-(naphthalen-1-yloxy)-3-thiophen-2-ylpropan-1-amine hydrochloride/(3S)-N-methyl-3-(naphthalen-1-yloxy)-3-(thiophen-2-yl)propan-1-amine hydrochloride (1:1)/(3S)-N-Methyl-3-(naphthalen-1-yloxy)-3-thiophen-2-ylpropan-1-aminhydrochlorid/Duloxetine hydrochloride/Duloxetine (hydrochloride)

IUPAC Name

Density

Solubility

Flash Point

235.7ºC

Boiling Point

466.2ºC at 760 mmHg

Melting Point

118-122ºC

InChl

InChl Key

BFFSMCNJSOPUAY-LMOVPXPDSA-N

WGK Germany

RID/ADR

HS Code Reference

Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:136434-34-9) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

No Technical Documents Available For This Product.

PMID

25952601

Abstract

Burning mouth syndrome (BMS) is mainly found in middle aged or elderly women and is characterized by intense burning or itching sensation of the tongue or other regions of the oral mucosa. It can be accompanied by xerostomia and dysgeusia. The syndrome generally manifests spontaneously, and the discomfort is typically of a continuous nature but increases in intensity during the evening and at night. Although BMS classically has been attributed to a range of factors, in recent years evidence has been obtained relating it peripheral (sensory C and/or trigeminal nerve fibers) or central neuropathic disturbances (involving the nigrostriatal dopaminergic system). The differential diagnosis requires the exclusion of oral mucosal lesions or blood test alterations that can produce burning mouth sensation. Patient management is based on the avoidance of causes of oral irritation and the provision of psychological support. Drug treatment for burning sensation in primary BMS of peripheral origin can consist of topical clonazepam, while central type BMS appears to improve with the use of antidepressants such as duloxetine, antiseizure drugs such as gabapentin, or amisulpride.

Title

Burning Mouth Syndrome: A Review and Update

Author

Francisco J Silvestre 1, Javier Silvestre-Rangil, Pia Lopez-Jornet

Publish date

2015 May 16

PMID

29053665

Abstract

Introduction: Many osteoarthritis patients continue to present symptoms despite nonsurgical treatment. Duloxetine might be a viable alternative for such cases, but real clinical relevance remains unclear.

Methods: A literature review was conducted in Epistemonikos, the largest database for systematic reviews in health that compiles multiple sources, including MEDLINE, EMBASE, and Cochrane, among others. Relevant data were extracted, and information from the primary studies was reanalyzed. A subsequent meta-analysis was conducted, and summary of findings tables were constructed using the GRADE methodology.

Results and conclusions: Four systematic reviews including four randomized trials, were identified. In conclusion, while duloxetine slightly improves pain and functionality in osteoarthritis patients, its use is associated with frequent adverse side effects. Therefore, the benefit/risk balance appears unfavorable.

Title

Is Duloxetine an Alternative in the Treatment of Osteoarthritis?

Author

Joaquin Ananias 1, Sebastian Irarrazaval 2

Publish date

2017 Oct 18

PMID

27854104

Abstract

Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most disabling and demoralizing problems that arise for cancer survivors. When investigating symptoms of numbness, tingling, or pain in the extremities, it is critical to determine whether the problem is neuropathic, somatic, or mixed. If the diagnosis is CIPN, it is important to weigh the potential benefits and harms of possible treatment options, and to devise an evidence-based multimodality treatment program. Such programs may include mixtures of opioid and nonopioid adjunctive medications, based on evidence from CIPN trials, and also extrapolation from trials in patients with other neuropathic pain syndromes-although such extrapolating must be done with caution, since other syndromes sometimes respond to agents that CIPN does not respond to. Other components of a successful program might include exercise; and possibly neuromodulation via acupuncture, spinal cord electrical stimulation, or neurocutaneous stimulation. There is good randomized trial evidence that most of the anticonvulsants and tricyclic antidepressants typically prescribed for neuropathic pain have little or no effect on CIPN, but there is some evidence of efficacy for duloxetine-however, clinical practice with regard to pharmacologic treatment of CIPN often does not reflect these data. We review here the recommendations of the American Society of Clinical Oncology, as well as some new and promising approaches to neuropathy, including new neuromodulation techniques.

Title

New Practical Approaches to Chemotherapy-Induced Neuropathic Pain: Prevention, Assessment, and Treatment

Author

Neil Majithia, Charles L Loprinzi, Thomas J Smith

Publish date

2016 Nov 15


Description :

Empty ...